FDA clears Biocon's Perjeta biosimilar, but US shelves wait until 2028
Biocon won FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, covering HER2-positive breast cancer from metastatic to early-stage disease. The catch: a patent settlement with Genentech pushes the earliest US launch to the third quarter of 2028.
- Original source: targetedonc.com.
- The source published it on Nov 16, 2026 at 7:00 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Biocon Limited has scored FDA approval for pertuzumab-qcay, sold as Pebrilzo, a biosimilar of Genentech's Perjeta. The agency cleared it for adults with HER2-positive breast cancer, spanning both metastatic and early-stage settings, Biocon announced on November 16, 2026.
In metastatic disease, Pebrilzo is indicated alongside trastuzumab (Herceptin) and docetaxel for patients who have not yet received anti-HER2 therapy or chemotherapy for metastatic disease. It is also approved in two early breast cancer settings: neoadjuvant use with trastuzumab and chemotherapy for locally advanced, inflammatory or early-stage tumors larger than 2 cm or node-positive disease as part of a complete regimen, and adjuvant treatment for early-stage patients at high risk of recurrence. Pertuzumab works as a monoclonal antibody that binds HER2 and blocks it from pairing with other HER family receptors, disrupting growth and survival signaling.
Biocon said the approval rested on structural and functional characterization, analytical similarity assessments and comparative clinical pharmacokinetic data, which it reported showed high similarity to the reference product with no clinically meaningful differences in quality, safety, efficacy or immunogenicity.
The FDA nod does not mean a fast US rollout. Under a global settlement and license agreement with Genentech announced October 14, 2026, which resolved disputes across the United States, Canada and other jurisdictions, Biocon named the third quarter of 2028 as the earliest licensed US launch date for Pebrilzo. The company put the earliest licensed launch in the European Union and United Kingdom at the first quarter of 2027, pending regulatory approval. The EMA's Committee for Medicinal Products for Human Use backed the 420-mg/14-mL infusion concentrate with a positive opinion in September 2026.
Pebrilzo arrives late to a race already underway. The FDA approved pertuzumab-dpzb (Poherdy) on November 13, 2025, making it the first Perjeta biosimilar and designating it interchangeable, which allows pharmacy-level substitution under state law. Shanghai Henlius' HLX11 is also in play, with the FDA accepting its biologics license application in February 2025.
HER2-positive disease accounts for roughly 15% to 20% of breast cancers, and the American Cancer Society estimates 321,910 people in the US will be diagnosed with invasive breast cancer in 2026. Biocon is also pursuing biosimilars to trastuzumab/hyaluronidase, nivolumab (Opdivo) and pembrolizumab (Keytruda). 'The U.S. FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon's journey to expand access to high-quality biosimilars,' said Shreehas Tambe, CEO and managing director of Biocon Limited.
TopicsBiocon Limited · Pebrilzo · pertuzumab-qcay · Genentech · Perjeta · Poherdy · Shreehas Tambe · FDA
Source: targetedonc.com
Written by AI from verified reporting.
More stories
- Health & science theepochtimes.com 0 viewsFDA Refuses to Approve Akeso-Summit Lung Cancer Drug After Survival Miss
- Health & science healthandme.com 0 viewsEurope approves Revolution Medicines' RAS-blocking pancreatic cancer pill
- Health & science wdsu.com 0 viewsFDA Greenlights First Treatment for Deadly Sanfilippo Syndrome
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR

